BDNF–VEGF interplay key to rapid antidepressant actions

A study by researchers at Yale University reveals a complex interplay of two different growth factors in the rapid and long-lasting antidepressant effects of ketamine. The study, published in Biological Psychiatry, reports that the antidepressant-like actions of brain-derived neurotrophic factor (BDNF) require the release of vascular endothelial growth factor (VEGF). “Surprisingly, the reciprocal relationship was also observed, indicating that BDNF–VEGF […]

Read more

Antiepileptic drugs linked to increased hospital stays in persons with Alzheimer’s disease

People with Alzheimer’s disease who used antiepileptic drugs had a higher number of accumulated hospital stays than people with Alzheimer’s disease who did not use antiepileptics, according to a new study from the University of Eastern Finland. The results were published in the Journal of American Medical Directors Association. During a two-year follow-up, persons who initiated antiepileptic drugs accumulated approximately […]

Read more

When your medications are the news

(HealthDay)—Would you stop taking a medication if you heard a negative news story about it? Sticking with a prescription drug regimen, or “medication adherence,” is already a challenge for many patients, with not taking medications as prescribed being a key reason people struggle to control chronic conditions. Adding to the problem, according to a Danish study, is that negative reports […]

Read more

Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.1 Sprycel is the only second-generation tyrosine kinase inhibitor approved […]

Read more

FDA Approves New Indication for Envarsus XR (tacrolimus extended-release tablets)

COPENHAGEN, Denmark, Dec. 19, 2018 /PRNewswire/ — Veloxis Pharmaceuticals announced today that the U.S. Food & Drug Administration (FDA) approved a new indication for Envarsus XR (tacrolimus extended-release tablets) to prevent organ rejection in de novo kidney transplant patients in combination with other immunosuppressants. This indication is commonly referred to as the de novo indication. Envarsus XR was approved for […]

Read more

Editorial: Stop allowing beliefs to get in the way of treating opioid use disorder

There is a breadth of academic research demonstrating that there are three medications that successfully treat opioid use disorder (OUD): methadone, buprenorphine, and naltrexone. However, patients face unnecessary barriers to evidence-based treatment from government regulations as well as providers’ own beliefs that are not grounded in science, researchers from the Grayken Center for Addiction at Boston Medical Center (BMC) said […]

Read more
1 2 3 4